Clinical Trial Update: Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on Catumaxomab for non-muscle-invasive bladder cancer in patients who failed or are intolerant to BCG, spanning Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Catumaxomab (Catumaxomab)

Snippet

Sponsor: LintonPharm Co.,Ltd. | Conditions: Bladder Cancer | Phase 1, Phase 2 | Status: UNKNOWN